ASIT Biotech S.A. announced that clinical development of gp-ASIT+™ in grass pollen allergy is on track. The phase III study conducted in Europe in adults is ongoing, with top line results expected by end 2019. The target of randomized patients (first injection of gp-ASIT+ or placebo) was reached before the start of the grass pollen season. Last patient last treatment visit is expected by end of April. Following the recent recommendations of Scientific Advisory Boards organized by ASIT biotech, the Company intends to initiate a follow-up study with gp-ASIT+™ in second quarter of 2019. This study should include the patients currently randomized in the phase III trial and contribute to evaluate the long-term benefits of ASIT biotech’s subcutaneous immunotherapy in patients suffering from grass-pollen rhinitis.